Ghahremani-Ghajar Mehrdad, Rojas-Bautista Vanessa, Lau Wei-Ling, Pahl Madeleine, Hernandez Miguel, Jin Anna, Reddy Uttam, Chou Jason, Obi Yoshitsugu, Kalantar-Zadeh Kamyar, Rhee Connie M
Division of Nephrology and Hypertension, University of California Irvine School of Medicine, Orange, California.
Nephrology Section, Veterans Affairs Long Beach Health Care System, Long Beach, California.
Semin Dial. 2017 May;30(3):262-269. doi: 10.1111/sdi.12591. Epub 2017 Mar 14.
Incremental hemodialysis has been examined as a viable hemodialysis regimen for selected end-stage renal disease (ESRD) patients. Preservation of residual kidney function (RKF) has been the driving impetus for this approach given its benefits upon the survival and quality of life of dialysis patients. While clinical practice guidelines recommend an incremental start of dialysis in peritoneal dialysis patients with substantial RKF, there remains little guidance with respect to incremental hemodialysis as an initial renal replacement therapy regimen. Indeed, several large population-based studies suggest that incremental twice-weekly vs. conventional thrice-weekly hemodialysis has favorable impact upon RKF trajectory and survival among patients with adequate renal urea clearance and/or urine output. In this report, we describe a case series of 13 ambulatory incident ESRD patients enrolled in a university-based center's Incremental Hemodialysis Program over the period of January 2015 to August 2016 and followed through December 2016. Among five patients who maintained a twice-weekly hemodialysis schedule vs. eight patients who transitioned to thrice-weekly hemodialysis, we describe and compare patients' longitudinal case-mix, laboratory, and dialysis treatment characteristics over time. The University of California Irvine Experience is the first systemically examined twice-weekly hemodialysis practice in North America. While future studies are needed to refine the optimal approaches and the ideal patient population for implementation of incremental hemodialysis, our case-series serves as a first report of this innovative management strategy among incident ESRD patients with substantial RKF, and a template for implementation of this regimen.
递增式血液透析已被作为一种可行的血液透析方案用于特定的终末期肾病(ESRD)患者。鉴于保留残余肾功能(RKF)对透析患者的生存及生活质量有益,这一方法一直是其主要推动因素。虽然临床实践指南建议对具有大量RKF的腹膜透析患者采用递增式开始透析,但对于递增式血液透析作为初始肾脏替代治疗方案的指导却很少。事实上,几项基于大人群的研究表明,对于有足够肾脏尿素清除率和/或尿量的患者,递增式每周两次与传统每周三次血液透析相比,对RKF轨迹和生存有有利影响。在本报告中,我们描述了一系列病例,13例非卧床初发ESRD患者于2015年1月至2016年8月期间参加了一所大学中心的递增式血液透析项目,并随访至2016年12月。在维持每周两次血液透析方案的5例患者与转为每周三次血液透析的8例患者中,我们描述并比较了患者随时间变化的纵向病例组合、实验室检查及透析治疗特征。加利福尼亚大学欧文分校的经验是北美首次对每周两次血液透析实践进行系统研究。虽然需要未来的研究来完善递增式血液透析实施的最佳方法和理想患者群体,但我们的病例系列是关于这一创新管理策略在具有大量RKF的初发ESRD患者中的首次报告,也是该方案实施的模板。